Eppendorf grows faster than the market
During the first half of 2017, the Eppendorf Group achieved group sales of €327.9 million (prior-year period: €305.5 million). At 7.3% (6.6% when adjusted for currency effects), growth in sales lay above average market growth in the life science industry. Income from operations (EBIT) climbed 9.1% to €63.2 million (prior-year period: €58.0 million), amounting to an EBIT margin of 19.3% (prior year: 19.0%). All of the Eppendorf Group’s market regions and product groups contributed to this positive overall development.
Thomas Bachmann, President & CEO of Eppendorf AG, was very pleased at this positive development: “The mid-year result shows that we outperformed the market during the first half of this year. We are currently working on digitalizing our product portfolio and the connectivity of our devices with our new generation of networked products, which we launched on the market during the first six months of the year. We are assuming that our business will continue to develop positively overall for the whole year 2017 and we expect growth to be higher than the industry average.”
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
La Jolla Institute finds previous seasonal flu infections may provide some level of H1N1 immunity

Sequential antibiotic therapy in the laboratory and in patients - Rapid switching between different antibiotics could prevent the evolution of resistance and lead to successful treatment of patients

dimes AUTOMATION GmbH - Bonn, Germany
Q Chip appoints Tim Sparey as Chief Executive Officer - Completes £2.0 Million Funding Round

Suffocating cancer cells - Self-assembling molecules could help in cancer therapy

HM-Software - Adelheidsdorf, Germany

Lumiphore, Inc. - Richmond, USA
